MYD88 and diffuse large B-cell lymphoma: ST2825 is a synthetic peptidomimetic compound that has been found to inhibit MyD88-dependent inflammatory signalling pathways and could have therapeutic potential for conditions such as systemic lupus erythematosus, traumatic brain injury and diffuse large B-cell lymphoma.45–48